Tengfei Li

Mr. Tengfei Li


Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
3 April 2025 in Journal of Evidence-Based Medicine
Verified
Journal Article
Closed access
TLTengfei Li
Tengfei Li
QZQingyong Zheng
Qingyong Zheng
JXJianguo Xu
Jianguo Xu
YLYiyi Li
Yiyi Li
MZMingyue Zhang
Mingyue Zhang
JTJinhui Tian
Jinhui Tian



18 October 2024 in European Heart Journal
Verified
Journal Article
Open access
PDF file
TLTengfei Li
Tengfei Li
JTJinhui Tian
Jinhui Tian
LZLi Zhou
Li Zhou
This commentary refers to ‘Subgroup effects of ticagrelor monotherapy for acute coronary syndrome using individual patient data from the TICO and T-PASS trials’, by Y.J. Lee et al., https://doi.org/10.1093/eurheartj/ehae685, and the discussion piece ‘Ticagrelor monotherapy for acute coronary syndrome: an individual patient data meta-analysis of TICO and T-PASS trials’, by Y.J. Lee et al., https://doi.org/10.1093/eurheartj/ehae249.

1 August 2026 in Diagnostics
Verified
Journal Article
Open access
PDF file
JXJianguo Xu
Jianguo Xu
DYDonghua Yang
Donghua Yang
QZQingyong Zheng
Qingyong Zheng
TLTengfei Li
Tengfei Li
YCYating Cui
Yating Cui
JTJinhui Tian
Jinhui Tian
Background: Staphylococcus aureus, including methicillin-resistant lineages, is a leading cause of device- and catheter-related infection, and rising resistance motivates the search for antimicrobial peptides (AMPs) with strong anti-staphylococcal activity and low host toxicity. Machine learning can prioritize candidate peptides. However, the literature-derived AMP datasets are prone to homology-driven optimism, and computational studies frequently overstate their translational reach. Methods: We curated 4007 deduplicated S. aureus-active AMP records and 582 binary-labeled hemolysis records. Each peptide was encoded with a transparent 538-dimensional physicochemical and compositional feature vector. Five classifiers and five regressors were evaluated for four endpoints (potency classification, log10 MIC regression, hemolysis classification, normalized hemolytic index) under both conventional random 5-fold cross-validation and homology-aware cross-validation, in which sequences were clustered by 3-mer similarity and whole clusters were confined to single folds. Class imbalance was handled by class weighting. Model behavior was interpreted with SHAP and Fisher-exact k-mer enrichment, and candidates were ranked by a multi-objective score that combines the independently trained heads. Results: Under homology-aware validation, performance was lower than under random splitting, as expected. Potency classification reached an AUROC of about 0.71 (Random Forest), compared with 0.797 under random cross-validation. Hemolysis classification remained strong at AUROC 0.90 (95% CI 0.88 to 0.93), which indicates that its high accuracy is not a homology leakage artifact. MIC regression was modest (homology-aware R2 0.17, Spearman ρ 0.39) and is therefore treated only as a rank-ordering signal. SHAP and k-mer analyses recovered interpretable structure–activity relationships. Net positive charge and amphipathicity drove potency, whereas bulk hydrophobicity drove hemolysis. Applying the pipeline to a generated pool prioritized 20 candidates. Nearest-neighbor analysis shows that these are close optimized variants of known potent scaffolds, with a median identity of 95% to a known peptide, rather than novel sequences. Conclusions: We present an interpretable, honestly benchmarked multi-objective pipeline that optimizes known anti-S. aureus AMP scaffolds toward lower predicted hemolysis. The prioritized peptides are computational hypotheses for future synthesis and experimental testing. Their low predicted hemolysis reflects a selection criterion rather than validated safety, and cross-species selectivity was not assessed.

24 June 2026 in Cochrane Database of Systematic Reviews
Verified
Journal Article
Open access
TLTengfei Li
Tengfei Li
JSJiyuan Shi
Jiyuan Shi
QZQingyong Zheng
Qingyong Zheng
JXJian-Guo Xu
Jian-Guo Xu
MZMingyue Zhang
Mingyue Zhang
ZLZheng Li
Zheng Li
This is a protocol for a Cochrane Review (intervention). The objectives are as follows: